Conclusions
METASTATIC BREAST CANCER
This final analysis of PUFFIN showed, as with the primary analysis, that overall efficacy was consistent with that of the ITT population in CLEOPATRA. Safety of pertuzumab remained consistent with the known pertuzumab profile. Overall, PUFFIN contributes to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit–risk profile of pertuzumab in Chinese patients.